KineMed, Inc. and CHDI Foundation, Inc. recently announced an extension of their collaboration that uses KineMed’s translational biomarker platform to characterize and track the pathogenesis of Huntington’s disease (HD) and evaluate potentially therapeutic interventions.
Two Contract Research Organizations (CROs) with leading expertise in molecular testing have decided to utilize the new Oncomine Cancer Research panel, which runs on Life Technologies Ion Torrent sequencing instruments, for clinical trial analyses and design.
Corgenix Medical Corporation (OTC BB: CONX.OB) recently announced in collaboration with Randox Laboratories that Randox has been granted CE Mark notification for its TxBCardio™ Assay. The TxBCardio test measures urinary levels of the thromboxane metabolite 11dhTxB2 to determine aspirin effect in apparently healthy individuals. CE mark designation enables commercial marketing and distribution of the product in Europe.
Almac Group Ltd.’s Diagnostics Business Unit recently announced the validated results of the ALM AADx assay, a gene expression test that identifies a subgroup of high grade serous ovarian cancer (HGSOC) patients that have a good prognosis following standard of care chemotherapy.
PGXL Technologies has formed a strategic partnership with NX PharmaGen Inc. (NXPG) to support the identification of biomarkers using their NeXosomeTM microparticle enrichment technology. Exosomes and microparticles, which are found in bodily fluids, will aid diagnosis and treatment of cancer, immunological disorders, preterm birth, diseases of the central nervous system and other medical conditions.